Streetbeat News

SPRY

ARS Pharmaceuticals, Inc.

https://ars-pharma.com

Industry

Biotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Open

15.64

Mkt cap

1.6B

Volume

570K

High

16.24

P/E Ratio

-34.34

52-wk high

17.08

Low

15.28

Div yield

N/A

52-wk low

3.38

Wall Street analysts have set an average price target for ARS Pharmaceuticals, Inc. (SPRY) that suggests a potential upside of 67.6%. This optimistic outlook is supported by positive trends in earnings estimate revisions.

Portfolio Pulse from

November 06, 2024 | 4:00 pm

ARS Pharmaceuticals is presenting seven abstracts on intranasal epinephrine at the 2024 ACAAI Annual Scientific Meeting, covering topics like cardiovascular safety and real-world data in pediatric patients.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:37 pm

ARS Pharmaceuticals (NASDAQ:SPRY) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $26.43. The company has shown significant revenue growth but struggles with profitability.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:50 pm

ARS Pharmaceuticals has announced that its Neffy Epinephrine Nasal Spray is now available by prescription in the U.S. This follows FDA approval for its use in treating Type I allergic reactions, including anaphylaxis.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:10 pm

Leerink Partners has maintained an 'Outperform' rating on ARS Pharmaceuticals and raised its price target from $21 to $25, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 1:49 pm

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 5:02 pm

ARS Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) for neffy 1 mg, aimed at treating Type I allergic reactions, including anaphylaxis, in children weighing 15 to 30 kg.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 8:49 pm

Analysts have provided mixed ratings for ARS Pharmaceuticals (NASDAQ:SPRY) over the past three months, with a recent average price target of $25.0. The company has shown significant revenue growth and maintains a strong financial position despite challenges in asset utilization.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:00 pm

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 4:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.